This is a working overview of counterion, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-31 and is reviewed periodically as new material appears.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised material; shade varies slightly between lots |
| Solubility in water | Freely soluble | Dissolves in water, saline, and aqueous buffers |
| Solubility in nonpolar solvents | Poorly soluble | Not compatible with oils or hydrocarbon solvents |
| Typical storage temperature | About −20 °C | Lyophilised, dry, dark storage slows hydrolysis |
| Common purity method | Reversed-phase HPLC | Area percentage, usually paired with mass spectrometry |
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
This is achieved, in part, by reactivating foetal haemoglobin production in place of the haemoglobin S that causes sickling. Hydroxyurea lowers the expression of adhesion molecules on endothelial and red blood cells, which lowers the chance of small vessel blockages. Additionally, it encourages the release of nitric oxide, which enhances blood flow and inhibits clot formation. Hydroxyurea had previously been used as a chemotherapy agent. Some concern exists that long-term use may be harmful. A Cochrane review in 2022 found a weak evidence base for its use in sickle cell disease. Despite expanding progress in gene therapy for SCD treatment, hydroxyurea remains a cornerstone first line therapy. However, it is severely underutilized despite the reduction of vaso-occlusive crises by approximately 44% and reduced hospitalizations. In 2019, the United States granted accelerated approval to the medication Voxelotor to treat sickle cell disease. It was approved by the European Medicines Agency (EMA) in 2021. In trials, it had been shown to have disease-modifying potential by increasing haemoglobin levels and decreasing hemolysis indicators However, following an increased risk of vaso-occlusive seizures and death observed in registries and clinical trials, the manufacturer, Pfizer, withdrew it from the market worldwide.
== Founding fathers of the United States == John Jay (King's 1764), president of the Continental Congress; first chief justice of the United States; author of five of The Federalist papers; first secretary of foreign affairs under the Articles of Confederation; architect of Jay Treaty with Great Britain Robert Livingston (King's 1764), a writer of the Declaration of Independence as part of the Committee of Five; first U.S. secretary of foreign affairs; negotiator of the Louisiana Purchase Egbert Benson (King's 1765), delegate to the Continental Congress, U.S. representative, first New York State attorney general, chief justice of the New York Supreme Court Gouverneur Morris (King's 1768), represented Pennsylvania in the Continental Congress; authored much of the United States Constitution; U.S. ambassador to France; United States senator from New York Alexander Hamilton* (King's 1776), American Revolutionary War officer, aide-de-camp to George Washington; most prolific writer of The Federalist Papers; first United States secretary of the treasury, portrayed on the ten-dollar bill; founder of the Bank of New York
== Career == Coon was a postdoctoral student in Donald Hunt's lab at the University of Virginia from 2002 to 2005. There Joshua Coon and John Syka developed electron-transfer dissociation (ETD). In 2005, Coon joined the University of Wisconsin-Madison. He became an associate professor in 2010, and a professor in 2012.
Sources: en.wikipedia.org
Supplementary motor area A region of the medial frontal cortex involved in the planning and coordination of complex, internally generated movements. The SMA contributes to motor sequence initiation, bimanual coordination, and motor imagery. Synapse The junction between two neurons (or between a neuron and another cell) where information is transmitted via neurotransmitters or electrical signals. Synaptic cleft The small space between the presynaptic and postsynaptic neurons across which neurotransmitters are released. Synaptic plasticity The ability of synapses to strengthen or weaken over time, based on activity levels. It underlies learning and memory. Synaptogenesis The formation of new synapses between neurons. It occurs extensively during development and continues throughout life in certain brain regions. Synaptopathy A disorder of synaptic function, often implicated in neurodevelopmental and neurodegenerative diseases such as autism and Alzheimer’s disease. Syringomyelia A condition in which a cyst forms within the spinal cord, potentially damaging nerve fibers and leading to pain, weakness, and sensory loss.
=== tio === tiocarlide (INN) tioclomarol (INN) tioconazole (INN) tioctilate (INN) Tiocystin tiodazosin (INN) tiodonium chloride (INN) tioguanine (INN) tiomergine (INN) tiomesterone (INN) tiomolibdate diammonium (USAN) tiomolibdic acid (USAN) tioperidone (INN) tiopinac (INN) tiopronin (INN) tiopropamine (INN) tiosalan (INN) tiospirone (INN) tiotidine (INN) tiotixene (INN) tiotropium bromide (INN) tioxacin (INN) tioxamast (INN) tioxaprofen (INN) tioxidazole (INN) tioxolone (INN)
== Side effects == Rarely, heart failure and stroke in association with use of methylephedrine have been reported. Methylephedrine shows reinforcing effects, a measure of addiction and misuse potential, in monkeys.
== Other uses == The trust-inducing property of oxytocin might help those with social anxiety and depression, anxiety, fear, and social dysfunctions, such as generalized anxiety disorder, post-traumatic stress disorder, and social anxiety disorder, as well as autism and schizophrenia, among others. However, a 2013 meta-analysis only autism spectrum disorder showed a significant combined effect size. A 2022 study found an indication of an effect among autistic children aged 3–5, but not among autistic children aged 5-12. People using oxytocin show improved recognition for positive social cues over threatening social cues and improved recognition of fear.
Sources: en.wikipedia.org
1993/3173) Education (Individual Pupils' Achievements) (Information) Regulations 1993 (S.I. 1993/3182) Education (European Economic Area) (Amendment) Regulations 1993 (S.I. 1993/3183) Education (European Economic Area) (Scotland) Regulations 1993 (S.I. 1993/3184) Liquor Licensing (Fees) (Scotland) Order 1993 (S.I. 1993/3185) Advice and Assistance (Assistance by Way of Representation) (Scotland) Amendment (No. 2) Regulations 1993 (S.I. 1993/3186) Advice and Assistance (Financial Limit) (Scotland) Regulations 1993 (S.I. 1993/3187) Education (Grant–maintained Schools) (Initial Sponsor Governors) Regulations 1993 (S.I. 1993/3188) Education (Acquisition of Grant-maintained Status) (Ballot Information) Regulations 1993 (S.I. 1993/3189) Supreme Court Fees (Amendment) Order 1993 (S.I. 1993/3191) Cod and Saithe (Specified Sea Areas) (Prohibition of Fishing) Order 1993 (S.I. 1993/3192) Haddock, Hake, Nephrops, Plaice and Sole (Specified Sea Areas) (Prohibition of Fishing) Order 1993 (S.I. 1993/3193) Social Security (Severe Disablement Allowance) Amendment Regulations 1993 (S.I. 1993/3194) Doncaster Borough Council (North Bridge Relief Road) (Crossing of Navigable Waterway (Sheffield and South Yorkshire Navigation River Don New Cut)) Scheme 1991 Confirmation Instrument 1993 (S.I. 1993/3195) Education (Distribution by Schools of Information about Further Education Institutions) (England) Regulations 1993 (S.I. 1993/3197) Nitrate Sensitive Areas (Designation) (Amendment) Order 1993 (S.I. 1993/3198) Broadcasting (Restrictions on the Holding of Licences) (Amendment) Order 1993 (S.I.
Okcuoglŭ, A.; Arcasoy, A.; Minnich, V.; Tarcon, Y.; Cin, S.; Yörükoğlu, O.; Demirag, B.; Renda, F. (August 1966). "Pica in Turkey. 1. The incidence and association with anemia". The American Journal of Clinical Nutrition. 19 (2): 125–131. doi:10.1093/ajcn/19.2.125. ISSN 0002-9165. PMID 5222998. Minnich, V.; Okçuoğlu, A.; Tarcon, Y.; Arcasoy, A.; Cin, S.; Yörükoğlu, O.; Renda, F.; Demirağ, B. (January 1968). "Pica in Turkey. II. Effect of clay upon iron absorption". The American Journal of Clinical Nutrition. 21 (1): 78–86. doi:10.1093/ajcn/21.1.78. ISSN 0002-9165. PMID 5237295. Glutathione synthesis
Cocaine overdose may cause seizures, abnormally high body temperature and a marked elevation of blood pressure, which can be life-threatening, abnormal heart rhythms, and death. Anxiety, paranoia, and restlessness can also occur, especially during the comedown. With excessive dosage, tremors, convulsions, and increased body temperature are observed.
Sources: en.wikipedia.org
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.
Reversed-phase HPLC is the standard approach, with purity expressed as a percentage of total peak area. Mass spectrometry confirms the expected molecular mass and can reveal adducts or truncated sequences. Neither method on its own establishes biological activity.
Small mass differences often reflect different counterions, such as acetate versus trifluoroacetate, or bound water rather than a different amino acid sequence. Mass spectrometry can distinguish these forms when the ionisation conditions are known. Exact sequence confirmation requires peptide mapping or tandem mass spectrometry.
The standard approach is reverse-phase high-performance liquid chromatography, reported as a percentage of total peak area. Because that figure alone says little about the nature of the impurities, the accompanying chromatogram is normally the more useful document for judging a batch.